Related Experiment Videos
Computer simulation of 57Fe bleomycin auger effects in DNA
M Terrissol1, E Pomplun, C Martin
1CPAT, Université Paul Sabatier, 118 route de Narbonne, 31062 Toulouse, France. terrissol@cpat.ups-tlse.fr
Radiation Protection Dosimetry
|August 27, 2002
Summary
Adding 57Fe to bleomycin enhances DNA double-strand breaks (DSBs) by releasing Auger electrons and X-rays. This study quanties the increased yield of DSBs using Monte Carlo simulations for potential therapeutic applications.
Area of Science:
- Nuclear physics applications in biology
- Radiation chemistry and DNA damage
- Computational biophysics
Background:
- Bleomycin is an antibiotic that induces DNA double-strand breaks (DSBs).
- Enhancing DSB yield is crucial for increasing bleomycin's therapeutic efficacy.
- Mössbauer spectroscopy using 57Fe can be employed to study these interactions.
Purpose of the Study:
- To evaluate the increase in DNA double-strand break (DSB) yield when 57Fe is incorporated into bleomycin.
- To quantify the contribution of Auger electrons and X-rays from 57Fe de-excitation to DNA damage.
- To model the direct and indirect damage mechanisms involved.
Main Methods:
- Monte Carlo simulation methods were utilized to model particle spectra and DNA damage yields.
- Calculations considered direct interactions with DNA and radical species from radiolysis.
- Analysis of Auger electron spectra to differentiate direct and indirect damage contributions.
Main Results:
- The Auger spectrum from 57Fe de-excitation contains low-energy electrons (<100 eV) causing direct DNA damage.
- Higher energy electrons (600-700 eV) contribute to indirect damage via radical species.
- An average of 0.65 DSBs per 57Fe de-excitation event was observed, with bleomycin receiving approximately 25% of the deposited energy.
Conclusions:
- Incorporating 57Fe into bleomycin significantly increases the yield of DNA double-strand breaks.
- The Auger electrons released play a dual role in direct and indirect DNA damage.
- This approach holds potential for enhancing the effectiveness of bleomycin-based therapies.